title: Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
authors.forename: David
authors.initials: D
authors.lastname: Peura
authors.forename: Francis K L
authors.initials: FK
authors.lastname: Chan
authors.forename: Charles Melbern
authors.initials: CM
authors.lastname: Wilcox
authors.forename: Liviu
authors.initials: L
authors.lastname: Niculescu
authors.forename: Manuela
authors.initials: M
authors.lastname: Berger
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy; D000068579:Celecoxib; D004008:Diclofenac / Q000009:adverse effects*; D006801:Humans; D009853:Omeprazole / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000139:chemically induced / Q000517:prevention & control*; D011720:Pyrazoles / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000009:adverse effects*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D011720:Pyrazoles; D013449:Sulfonamides; D004008:Diclofenac; D000068579:Celecoxib; D009853:Omeprazole